Daniela J Carroll1, Jeremy A O'Sullivan1, David B Nix2, Yun Cao1, Michael Tiemeyer2, Bruce S Bochner3. 1. Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Ill. 2. Complex Carbohydrate Research Center, University of Georgia, Athens, Ga. 3. Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Ill. Electronic address: bruce.bochner@northwestern.edu.
Abstract
BACKGROUND: Siglec-8 is a CD33 subfamily cell-surface receptor selectively expressed on human eosinophils. After cytokine priming, Siglec-8 mAb or glycan ligand binding causes eosinophil apoptosis associated with reactive oxygen species (ROS) production. Most CD33-related Siglecs function as inhibitory receptors, but the ability of Siglec-8 to stimulate eosinophil ROS production and apoptosis suggests that Siglec-8 might instead function as an activating receptor. OBJECTIVE: We sought to determine the role of IL-5 priming and identify the signaling molecules involved in Siglec-8 function for human eosinophils. METHODS: We used an mAb and/or a multimeric synthetic sulfated sialoglycan ligand recognizing Siglec-8 in combination with integrin blocking antibodies, pharmacologic inhibitors, phosphoproteomics, and Western blot analysis to define the necessity of various proteins involved in Siglec-8 function for human eosinophils. RESULTS: Cytokine priming was required to elicit the unanticipated finding that Siglec-8 engagement promotes rapid β2-integrin-dependent eosinophil adhesion. Also novel was the finding that this adhesion was necessary for subsequent ROS production and apoptosis. Siglec-8-mediated ROS was generated through reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation because pretreatment of eosinophils with catalase (an extracellular superoxide scavenger) or NSC 23766 (a Rac GTPase inhibitor) completely inhibited Siglec-8-mediated eosinophil apoptosis. Finally, engagement of Siglec-8 on IL-5-primed eosinophils resulted in increased phosphorylation of Akt, p38, and c-Jun N-terminal kinase 1 that was also β2-integrin dependent; pharmacologic inhibition of these kinases completely prevented Siglec-8-mediated eosinophil apoptosis. CONCLUSIONS: These data demonstrate that Siglec-8 functions uniquely as an activating receptor on IL-5-primed eosinophils through a novel pathway involving regulation of β2-integrin-dependent adhesion, NADPH oxidase, and a subset of protein kinases.
BACKGROUND:Siglec-8 is a CD33 subfamily cell-surface receptor selectively expressed on human eosinophils. After cytokine priming, Siglec-8 mAb or glycan ligand binding causes eosinophil apoptosis associated with reactive oxygen species (ROS) production. Most CD33-related Siglecs function as inhibitory receptors, but the ability of Siglec-8 to stimulate eosinophil ROS production and apoptosis suggests that Siglec-8 might instead function as an activating receptor. OBJECTIVE: We sought to determine the role of IL-5 priming and identify the signaling molecules involved in Siglec-8 function for human eosinophils. METHODS: We used an mAb and/or a multimeric synthetic sulfated sialoglycan ligand recognizing Siglec-8 in combination with integrin blocking antibodies, pharmacologic inhibitors, phosphoproteomics, and Western blot analysis to define the necessity of various proteins involved in Siglec-8 function for human eosinophils. RESULTS: Cytokine priming was required to elicit the unanticipated finding that Siglec-8 engagement promotes rapid β2-integrin-dependent eosinophil adhesion. Also novel was the finding that this adhesion was necessary for subsequent ROS production and apoptosis. Siglec-8-mediated ROS was generated through reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation because pretreatment of eosinophils with catalase (an extracellular superoxide scavenger) or NSC 23766 (a Rac GTPase inhibitor) completely inhibited Siglec-8-mediated eosinophil apoptosis. Finally, engagement of Siglec-8 on IL-5-primed eosinophils resulted in increased phosphorylation of Akt, p38, and c-Jun N-terminal kinase 1 that was also β2-integrin dependent; pharmacologic inhibition of these kinases completely prevented Siglec-8-mediated eosinophil apoptosis. CONCLUSIONS: These data demonstrate that Siglec-8 functions uniquely as an activating receptor on IL-5-primed eosinophils through a novel pathway involving regulation of β2-integrin-dependent adhesion, NADPH oxidase, and a subset of protein kinases.
Authors: M W Johansson; K A Gunderson; E A B Kelly; L C Denlinger; N N Jarjour; D F Mosher Journal: Clin Exp Allergy Date: 2013-03 Impact factor: 5.018
Authors: Emily M Wilkerson; Mats W Johansson; Alexander S Hebert; Michael S Westphall; Sameer K Mathur; Nizar N Jarjour; Elizabeth A Schwantes; Deane F Mosher; Joshua J Coon Journal: J Proteome Res Date: 2016-04-01 Impact factor: 4.466
Authors: Charlotte Marx; Julia Novotny; Danby Salbeck; Katie R Zellner; Leo Nicolai; Kami Pekayvaz; Badr Kilani; Sven Stockhausen; Niklas Bürgener; Danny Kupka; Thomas J Stocker; Ludwig T Weckbach; Joachim Pircher; Markus Moser; Michael Joner; Walter Desmet; Tom Adriaenssens; Franz-Josef Neumann; Anthony H Gerschlick; Jurrien M Ten Berg; Michael Lorenz; Konstantin Stark Journal: Blood Date: 2019-11-21 Impact factor: 22.113
Authors: Fanny Legrand; Nadine Landolina; Ilan Zaffran; Robert O Emeh; Elizabeth Chen; Amy D Klion; Francesca Levi-Schaffer Journal: Allergy Date: 2019-02-26 Impact factor: 13.146
Authors: Mats W Johansson; Elizabeth A Kelly; Christopher L Nguyen; Nizar N Jarjour; Bruce S Bochner Journal: Int Arch Allergy Immunol Date: 2018-06-07 Impact factor: 2.749
Authors: Paneez Khoury; Praveen Akuthota; Steven J Ackerman; Joseph R Arron; Bruce S Bochner; Margaret H Collins; Jean-Emmanuel Kahn; Patricia C Fulkerson; Gerald J Gleich; Rashmi Gopal-Srivastava; Elizabeth A Jacobsen; Kristen M Leiferman; Levi-Schaffer Francesca; Sameer K Mathur; Michael Minnicozzi; Calman Prussin; Marc E Rothenberg; Florence Roufosse; Kathleen Sable; Dagmar Simon; Hans-Uwe Simon; Lisa A Spencer; Jonathan Steinfeld; Andrew J Wardlaw; Michael E Wechsler; Peter F Weller; Amy D Klion Journal: J Leukoc Biol Date: 2018-04-19 Impact factor: 4.962
Authors: Fanny Legrand; Yun Cao; Joshua B Wechsler; Xiang Zhu; Nives Zimmermann; Shakuntala Rampertaap; Joseph Monsale; Kimberly Romito; Bradford A Youngblood; Emily C Brock; Michelle A Makiya; Nenad Tomasevic; Christopher Bebbington; Irina Maric; Dean D Metcalfe; Bruce S Bochner; Amy D Klion Journal: J Allergy Clin Immunol Date: 2018-12-10 Impact factor: 10.793
Authors: Corwin M Nycholat; Shiteng Duan; Eva Knuplez; Charli Worth; Mila Elich; Anzhi Yao; Jeremy O'Sullivan; Ryan McBride; Yadong Wei; Steve M Fernandes; Zhou Zhu; Ronald L Schnaar; Bruce S Bochner; James C Paulson Journal: J Am Chem Soc Date: 2019-08-30 Impact factor: 15.419
Authors: Sheena C Kerr; Jeanmarie R Gonzalez; Julia Schanin; Michael C Peters; Bart N Lambrecht; Emily C Brock; Annabelle Charbit; K M Ansel; Bradford A Youngblood; John V Fahy Journal: Clin Exp Allergy Date: 2020-07-08 Impact factor: 5.018